Clinical Trials Browser

Phase 3 × lanreotide × Clear all

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT06807437 2025-12-05

Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

Phase 3 Recruiting

274 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06878664 2025-09-02

RIALTO

Phase 3 Recruiting

166 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT00353496 2025-03-05

CLARINET

Phase 3 Completed

264 enrolled 17 charts

Endocrine Tumors

NCT00774930 2022-10-14

ELECT

Phase 3 Completed

115 enrolled 17 charts

EndocrineNET

Carcinoid Tumor, Diarrhea, Flushing, Neuroendocrine Tumors, Serotonin Syndrome

NCT00842348 2022-10-12

NET729

Phase 3 Completed

89 enrolled 9 charts

EndocrineNET

Neuroendocrine Tumors

NCT02683941 2022-07-06

SPINET

Phase 3 Terminated

77 enrolled 20 charts

EndocrineNET

Neuroendocrine Tumors in Lung

NCT00216372 2020-11-05

Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis

Phase 3 Completed

80 enrolled

Gynecologic

Carcinoma, Intestinal Obstruction, Peritoneal Neoplasms

NCT04065165 2020-02-05

TELEFIRST

Phase 3 Withdrawn

Endocrine

Carcinoid Heart Disease, Serotonin Syndrome

NCT01313273 2019-11-22

POSEIDON

Phase 3 Terminated

3 enrolled 4 charts

Genitourinary

Prostatic Neoplasms

NCT03439709 2018-03-01

MERGE

Phase 3 Unknown

90 enrolled

Endocrine

Acromegaly, Pituitary Neoplasms, Growth Hormone-Secreting Pituitary Adenoma

Clinical Trials

ACTION-1

Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

RIALTO

CLARINET

ELECT

NET729

SPINET

Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis

TELEFIRST

POSEIDON

MERGE